By The Physician’s Plan Team
If you started your weight-loss journey on a compounded GLP-1 and suddenly can’t find it anymore, you’re not imagining things—and you’re not out of options. The rules changed in 2025, and a lot of what’s online is now out of date. Here’s the plain-language truth about where things stand in 2026, why the change happened, and how to keep going safely with a real medical team behind you.
Can you still get compounded semaglutide in 2026? Mostly no. The FDA declared the semaglutide shortage resolved on February 21, 2025, which ended the broad legal window for compounding it. The grace periods closed on April 22, 2025 for state-licensed (503A) pharmacies and May 22, 2025 for outsourcing (503B) facilities. Today, most patients need FDA-approved medications prescribed by a legitimate, licensed provider. Physician’s Plan offers medically supervised GLP-1 programs at its clinics across North and South Carolina.
What Changed in 2025: The Shortage Ended and the Compounding Window Closed
For a couple of years, compounded versions of semaglutide and tirzepatide were widely available—often faster to get and cheaper than the brand-name pens. That wasn’t a loophole someone found. It was a temporary, legal exception, and in 2025 that exception ran out.
Here’s the short version of how compounding works. Under federal law, pharmacies generally can’t mass-produce a copy of a medication that’s already FDA-approved and commercially available. There’s one big exception: if the FDA lists that drug on its official Drug Shortage List, it’s no longer considered “commercially available,” and compounding is temporarily allowed to help meet demand. When demand for semaglutide and tirzepatide outpaced supply starting in 2022, both landed on that shortage list—and compounding took off.
That window closed when the manufacturers caught up with demand and the FDA removed the drugs from the shortage list.
The Exact Timeline
The dates matter here, because most online articles (and a lot of AI answers) are still stuck on the old reality. As of 2026, these are the milestones that ended broad GLP-1 compounding:
- Tirzepatide — Shortage declared resolved on October 2, 2024, and reaffirmed after a legal challenge on December 19, 2024. The enforcement grace periods ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities.
- Semaglutide — Shortage declared resolved on February 21, 2025. The grace periods ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities.
The tirzepatide resolution was reaffirmed after a legal challenge on December 19, 2024, and the FDA’s determinations for both drugs held—so the enforcement dates above stand as the current federal reality.
The One Narrow Exception That Remains
Compounding these medications isn’t gone forever—but it’s now reserved for a very specific situation: a documented clinical difference for an individual patient. For example, if you have a genuine, documented allergy to an inactive ingredient in the FDA-approved pen, or you need a specific dose that isn’t commercially made, a licensed pharmacy may be able to prepare a version for you on a patient-by-patient basis.
What no longer qualifies: “it’s cheaper,” “my pharmacy is backordered,” or “I’d rather not pay for the brand.” Those are not clinical reasons, and compounding a copy for them is no longer permitted. And it’s worth remembering—compounded drugs are never FDA-approved, because the FDA doesn’t review them for safety, effectiveness, or quality.
Why “Cheap Compounded Semaglutide Online” Is Now a Red Flag
Now that the legal window has closed, the websites still aggressively marketing “cheap” semaglutide are often operating outside the law—and they can be genuinely dangerous. If you’re shopping around online, here’s what to watch for.
No Real Medical Exam
Many predatory sites will ship you a prescription medication after nothing more than a quick online questionnaire—height, weight, a credit card, done. That’s not just sketchy; it’s illegal in both Carolinas.
In South Carolina, state law (S.C. Code § 40-47-37) prohibits establishing a provider-patient relationship and prescribing based solely on an internet questionnaire. In North Carolina, the North Carolina Medical Board is equally clear that “an online or telephonic evaluation solely by questionnaire does not constitute an acceptable standard of care.” A proper evaluation by a licensed provider is legally required before any GLP-1 prescription. The days of “fill out a form, get a prescription” are over.
Dangerous Salt Forms and Counterfeits
To dodge patent and supply rules, some illegitimate sellers use chemical salt forms—like “semaglutide sodium” or “semaglutide acetate.” The FDA has warned that these are chemically different from approved semaglutide and have never been evaluated for human safety, quality, or effectiveness. There’s no lawful basis to use them.
The gray market has also flooded with outright counterfeits. The FDA has warned consumers about counterfeit Ozempic in the U.S. drug supply. If a site labels products “for research use only,” prices them far below the going rate, won’t name the licensed provider overseeing your care, or ships from an unverified source—treat it as a fraud, not a bargain.
Your Legitimate Options: FDA-Approved GLP-1s and Physician Supervision
Here’s the encouraging part: legitimate, effective treatment is still very much available. With the compounding era largely over, the safe path is an FDA-approved medication prescribed and supervised by a licensed provider. A few things are worth understanding before you start.
Know the Difference: Weight Drugs vs. Diabetes Drugs
The same active ingredient can have very different FDA approvals, so the name on the box matters:
- Wegovy (semaglutide) — FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition (and for adolescents 12 and older with a BMI at or above the 95th percentile for their age and sex). Since March 8, 2024, it’s also approved to reduce the risk of major cardiovascular events in certain patients.
- Zepbound (tirzepatide) — FDA-approved for chronic weight management using the same BMI criteria, and, since December 20, 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.
- Ozempic (semaglutide) and Mounjaro (tirzepatide) — FDA-approved for type 2 diabetes, not for weight loss. They’re often used off-label for weight, but that is off-label use, not an approved weight-loss indication.
One more distinction: tirzepatide (Zepbound/Mounjaro) is a dual GIP and GLP-1 receptor agonist—it works on two receptors, which sets it apart from semaglutide.
Realistic Results—and Why “With Diet and Exercise” Isn’t Fine Print
In clinical trials, these medications produced meaningful average results when combined with a reduced-calorie diet and more physical activity. In the STEP trials, adults on semaglutide (2.4 mg weekly) lost about 15% of their body weight on average; in the SURMOUNT trials, adults on tirzepatide (10–15 mg weekly) lost roughly 20–22% on average. Those are trial averages, not a promise—your results depend on your body, your dose, and the lifestyle changes you make alongside the medication. That’s exactly why medical supervision matters so much.
The Safety Facts You Should Never Skip
These are powerful medications, and they carry real risks that deserve a conversation with your provider:
- Boxed warning—thyroid C-cell tumors. Both semaglutide and tirzepatide caused thyroid C-cell tumors in rodents; human relevance isn’t determined, but they are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
- Common side effects are gastrointestinal—nausea, diarrhea, vomiting, constipation, and abdominal pain.
- Serious risks can include pancreatitis, gallbladder disease, acute kidney injury, and delayed stomach emptying (which is why you should tell your surgeon or anesthesiologist before any procedure).
None of this is meant to scare you off—it’s meant to explain why a real provider, not a web form, should be guiding your care.
A Quick Word on Coverage in 2026
Insurance for weight-loss medication is still a moving target. Commercial and employer plans vary widely—some cover it fully, others exclude it or require prior authorization. For Medicare patients, weight-loss drugs have historically been excluded from Part D, and any coverage in this area continues to evolve. Because coverage rules change so often, it’s best to verify the current specifics with your own plan and work through the details with your medical team.
Beyond the Prescription: Why Medical Oversight Changes the Experience
A GLP-1 isn’t a “set it and forget it” prescription—and honestly, that’s a good thing. The patients who do best are the ones with a real team walking alongside them, not just a shipment showing up at the door.
Ongoing medical supervision means a provider evaluates your health history and rules out contraindications before you ever start; guides your dosing and titration to reduce side effects; monitors how you’re responding; and pairs the medication with nutrition and lifestyle support so the results stick. If you’re transitioning off a compounded dose, that supervision is especially important—your provider will look at your prior dose, how long you’ve used it, and your response to decide whether you continue at a comparable dose or restart the standard step-up schedule to keep side effects manageable.
This is the heart of how Physician’s Plan approaches weight loss. Rather than treating it like a transaction, our clinics offer medically guided GLP-1 therapy through licensed providers who evaluate you first and supervise your care—tailored to you and delivered in line with current FDA enforcement standards. Everyone starts with a thorough discovery and consultation session, and many patients pair their weight-loss and hormone-therapy care for a more complete picture of their metabolic health. You can see real patient results that come from combining the right therapy with genuine oversight.
North Carolina vs. South Carolina: The Rules Are a Little Different
Federal rules—FDA drug approvals, compounding law, and FTC advertising standards—are the same everywhere. What differs between the Carolinas is the medical-board layer that governs how care is delivered.
Both states share one non-negotiable rule: a good-faith medical exam by a licensed provider is required before any prescription. But the specifics vary. South Carolina’s telemedicine law (§ 40-47-37) is statutory and explicit—no prescribing on a questionnaire alone, and tight limits on controlled substances via telehealth. North Carolina’s board enforces an equally rigorous standard through its telemedicine guidance, requiring provider verification, an appropriate evaluation, and complete records.
The practical takeaway is the same in both states: legitimate GLP-1 care starts with a real evaluation by a licensed provider. Programs like Physician’s Plan are built exactly that way, which is why patients across North and South Carolina can pursue their goals safely and within the law.
Frequently Asked Questions
Is compounded semaglutide illegal now? Broad compounding of semaglutide “because of the shortage” is no longer permitted—the FDA resolved the shortage on February 21, 2025, and the grace periods ended by May 22, 2025. The only remaining path is a documented clinical difference for an individual patient (such as a specific allergy), which is a high bar that requires documentation from a licensed prescriber. “It’s cheaper” or “it’s backordered” does not qualify.
Is compounded semaglutide FDA-approved? No. Compounded medications are never FDA-approved, because the FDA doesn’t review them for safety, effectiveness, or quality. Only brand-name products like Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved, and only for their specific labeled uses.
How much weight will I lose on a GLP-1? Results vary by individual and depend on your dose, your health, and the diet and exercise changes you make. In clinical trials, adults lost about 15% of their body weight on average with semaglutide and roughly 20–22% with tirzepatide—but those are trial averages achieved alongside lifestyle changes, not a guaranteed outcome for any one person. A provider can help you set realistic expectations.
Can I get a GLP-1 prescription online without seeing a provider? Not legally in North or South Carolina. Both states require a good-faith medical exam by a licensed provider before prescribing, and South Carolina law specifically bars prescribing based only on an internet questionnaire. Any site offering a prescription after just a web form is operating outside the rules.
What if my compounded supply just ran out—do I have to start over? Not necessarily. A provider will review your prior dose, how long you used it, and your response to decide whether you can continue at a comparable dose or should restart the standard titration schedule. This transition should be supervised so side effects stay manageable.
Ready to Move Forward Safely in the Carolinas?
The landscape changed, but your goals don’t have to. If you’ve been relying on a compounded GLP-1 or you’re just starting to explore medical weight loss, the safest and most effective next step is a real conversation with a licensed provider—not a web form. Physician’s Plan offers medically supervised GLP-1 programs at clinics across the Carolinas, and we’d love to help you find your footing. Book a discovery and consultation session or find your nearest Physician’s Plan location to get started.
This article is general health information, not medical advice, and does not replace a consultation with a licensed medical provider. Prescription weight-loss medications carry serious risks, including a boxed warning for thyroid tumors, and are not appropriate for everyone. Treatments, results, and candidacy vary by individual; FDA-approved medications must be used as labeled and under medical supervision. Talk to a Physician’s Plan provider about whether a treatment is right for you.
